Diverse healthcare structures and reimbursement pathways in Europe present unique challenges for medical device companies. Varying reimbursement frameworks, technology assessment processes, and funding mechanisms can complicate the rollout of new treatments. This White Paper provides a detailed case study on how developers of medical technology (specifically – implants) can successfully navigate reimbursement pathways in key European markets, focusing on France.
Key highlights of this case study include:
- General overview of the market access environment in France
- Integration of procedure coding within the CCAM classification
- Evolution of DRG-based reimbursement for transarterial and transapical TAVI approaches
- Creation and expansion of brand-specific reimbursement categories via the LPPR list
- Role of early-stage funding and HTA in enabling access (PSTIC - PRME)
- Summary of major reimbursement milestones from 2007 to 2024
Navigating the French reimbursement landscape requires a deep understanding of coding, innovation funding, DRG and add-on reimbursement dynamics. Failure to address these factors can lead to delays, revenue loss, and limited patient access. This White Paper provides actionable strategies and proven solutions to help MedTech companies secure timely market access and reimbursement for high-impact technologies.
Gain a competitive edge and optimize your market access strategy with practical insights from industry experts.
Request White Paper
Request an analytical White Paper and advance your understanding of European market access for medical devices